Search
Publications
For the subgroup Rare hereditary blood cancers:
GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.
EHA Ranking 2025
The information on this page is also available as a printable PDF. EHA Ranking 2025 — PDF version
Position
Company
Priority points
Corporate Level
1
Johnson & Johnson
1. 488,82
Platinum
2
Bristol Myers Squibb
1.
I4MDS consortium: advancing MDS treatment and understanding
The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.
Read more7th European CAR T-cell Meeting
The European Hematology Association (EHA) and the EBMT are excited to announce the 7th edition of the jointly organized European CAR T-cell Meeting.
Read moreSelected EMA news
November 2024New medicines recommended for approval
Eltrombopag Viatris (eltrombopag) – generic
Treatment of primary immune thrombocytopenia and thrombocytopenia associated with chronic hepatitis C (disease in which patients have low levels of blood platelets)
Alhemo (concizumab)
Prevention of bleeding in patients with hemophilia A…